AI Article Synopsis

  • Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is primarily linked to mutations in the CXCR4 gene, leading to immune system issues.
  • Research evaluated how different CXCR4 mutations affect physical symptoms and the potential of a drug called mavorixafor to mitigate these effects.
  • Results indicated that all tested CXCR4 variants had impaired functioning, with a clear connection between the severity of immune symptoms and specific CXCR4 internalization issues, suggesting potential new biomarkers for the syndrome.*

Article Abstract

Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency predominantly caused by heterozygous gain-of-function mutations in CXCR4 C-terminus. We assessed genotype-phenotype correlations for known pathogenic CXCR4 variants and in vitro response of each variant to mavorixafor, an investigational CXCR4 antagonist. We used cell-based assays to analyze CXCL12-induced receptor trafficking and downstream signaling of 14 pathogenic CXCR4 variants previously identified in patients with WHIM syndrome. All CXCR4 variants displayed impaired receptor trafficking, hyperactive downstream signaling, and enhanced chemotaxis in response to CXCL12. Mavorixafor inhibited CXCL12-dependent signaling and hyperactivation in cells harboring CXCR4 mutations. A strong correlation was found between CXCR4 internalization defect and severity of blood leukocytopenias and infection susceptibility, and between AKT activation and immunoglobulin A level and CD4 T-cell counts. This study is the first to show WHIM syndrome clinical phenotype variability as a function of both CXCR4 genotype diversity and associated functional dysregulation. Our findings suggest that CXCR4 internalization may be used to assess the pathogenicity of CXCR4 variants in vitro and also as a potential WHIM-related disease biomarker. The investigational CXCR4 antagonist mavorixafor inhibited CXCL12-dependent signaling in all tested CXCR4-variant cell lines at clinically relevant concentrations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519442PMC
http://dx.doi.org/10.1038/s41435-022-00181-9DOI Listing

Publication Analysis

Top Keywords

cxcr4 variants
20
cxcr4
12
genotype-phenotype correlations
8
pathogenic cxcr4
8
variants vitro
8
investigational cxcr4
8
cxcr4 antagonist
8
receptor trafficking
8
downstream signaling
8
mavorixafor inhibited
8

Similar Publications

Background: Head and neck squamous cell carcinoma (HNSCC) presents significant treatment challenges, particularly in cases unrelated to human papillomavirus (HPV). The chemokine receptor CXCR4, interacting with its ligand CXCL12, plays a crucial role in tumor proliferation, metastasis, and treatment resistance. This study explores the therapeutic potential of engineered monomeric and dimerized CXCL12 variants (CXCL12 and CXCL12, respectively) in HNSCC and evaluates potential additive effects when combined with radiation therapy.

View Article and Find Full Text PDF

CXCR4, a chemokine receptor known as Fusin or CD184, spans the outer membrane of various human cells, including leukocytes. This receptor is essential for HIV infection as well as for many vital cellular processes and is implicated to be associated with multiple pathologies, including cancers. This study employs various computational tools to investigate the molecular effects of disease-vulnerable germ-line missense and non-coding SNPs of the CXCR4 gene.

View Article and Find Full Text PDF

Background: Despite recurrent and activating mutations, including MYD88, CXCR4, ARID1A, KMT2D, and CD79B were identified, the genetic basis for Waldenström's Macroglobulinemia (WM) and the risk of progression of IgM MGUS to WM remain to be fully elucidated.

Methods: We investigated the mutation status of WM (n = 8), sWM (n = 7), and IgM MGUS (n = 5) patients, by performing high-throughput targeted AmpliSeq NGS on 117 target genes. Specifically, we analyzed the CD19+ cells from 15 WM/sWM patients and five IgM MGUS patients.

View Article and Find Full Text PDF

The chemokine CXCL12 and its two cognate receptors - CXCR4 and ACKR3 - are key players in various homeostatic and pathophysiological processes, including embryonic development, autoimmune diseases, tissue repair and cancer. Recent reports identified an interaction of CXCR4 and ACKR3 with receptor activity-modifying proteins (RAMPs), and RAMP3 has been shown to facilitate ACKR3's recycling properties. Yet, the functional effects of RAMPs on the CXCL12 signalling axis remain largely elusive.

View Article and Find Full Text PDF

Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia characterized by the accumulation of neoplastic mature B cells in blood, bone marrow, lymph nodes, and spleen. The disease biology remains unresolved in many aspects, including the processes underlying the disease progression and relapses. However, studying CLL poses a considerable challenge due to its complexity and dependency on the microenvironment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!